SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies
Sign Up to like & getrecommendations! Published in 2022 at "American Journal of Hematology"
DOI: 10.1002/ajh.26669
Abstract: Patients with B‐cell malignancies have suboptimal immune responses to SARS‐CoV‐2 vaccination and are a high‐risk population for severe COVID19 disease. We evaluated the effect of a third booster BNT162b2 vaccine on the kinetics of anti‐… read more here.
Keywords: patients cell; booster bnt162b2; cell malignancies; humoral responses ... See more keywords
Severe COVID-19 in Patients with B Cell Alymphocytosis and Response to Convalescent Plasma Therapy
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Clinical Immunology"
DOI: 10.1007/s10875-020-00904-5
Abstract: To the Editor, The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for coronavirus disease 2019 (COVID-19), has resulted in a global pandemic. In most cases, COVID-19 is a self-limited infection… read more here.
Keywords: covid patients; cell alymphocytosis; covid; patients cell ... See more keywords
Pharmacokinetics of obinutuzumab in Chinese patients with B‐cell lymphomas
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.13232
Abstract: Aim The Phase Ib GERSHWIN study (NCT01680991) assessed the pharmacokinetic (PK) profile of obinutuzumab following multiple intravenous (i.v.) doses to Chinese patients with B‐cell lymphomas, and compared findings with previous obinutuzumab PK studies in mainly… read more here.
Keywords: cell lymphomas; non chinese; pharmacokinetics obinutuzumab; chinese patients ... See more keywords
A phase 1/2 trial of ublituximab, a novel anti‐CD20 monoclonal antibody, in patients with B‐cell non‐Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab
Sign Up to like & getrecommendations! Published in 2017 at "British Journal of Haematology"
DOI: 10.1111/bjh.14534
Abstract: This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti‐tumour activity of ublituximab, a unique type I, chimeric, glycoengineered anti‐CD20 monoclonal antibody, in rituximab‐relapsed or ‐refractory patients with B‐cell non‐Hodgkin lymphoma (B‐NHL) or chronic… read more here.
Keywords: cell non; anti cd20; cd20 monoclonal; non hodgkin ... See more keywords
Parsaclisib Has Activity in Patients with B-cell Malignancies.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-rw2019-031
Abstract: A next-generation PI3Kδ inhibitor achieved objective responses and long-term tolerability in NHL. read more here.
Keywords: parsaclisib activity; cell malignancies; patients cell; activity patients ... See more keywords
Case series of unique adverse events related to the use of ibrutinib in patients with B-cell malignancies—A single institution experience and a review of literature
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Oncology Pharmacy Practice"
DOI: 10.1177/1078155218788707
Abstract: Background Ibrutinib, a Bruton’s tyrosine kinase inhibitor has reformed the treatment of various B-cell malignancies including chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom’s macroglobulinemia. Although generally well tolerated, here we describe our institutional experience… read more here.
Keywords: cell malignancies; unique adverse; treatment; case series ... See more keywords
Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial
Sign Up to like & getrecommendations! Published in 2018 at "Haematologica"
DOI: 10.3324/haematol.2017.185801
Abstract: Risk-stratification and treatment intensification according to minimal residual disease (MRD) analysis has improved outcomes of patients with acute lymphoblastic leukemia (ALL).[1][1],[2][2] However, a significant proportion of patients with T-cell ALL (T-ALL) still experience early relapse… read more here.
Keywords: impact absence; lymphoblastic leukemia; acute lymphoblastic; patients cell ... See more keywords
Clinical Management of Patients With B-Cell Depletion Agents to Treat or Prevent Prolonged and Severe SARS-COV-2 Infection: Defining a Treatment Pathway
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.911339
Abstract: Introduction Immunocompromised patients with B-cell depletion agents are at risk for persistence and/or severe SARS-COV-2 infection. We describe a case series of 21 COVID-19 patients under B cell depletion therapy, mostly treated with a combined… read more here.
Keywords: cov infection; patients cell; sars cov; cell depletion ... See more keywords
Prognostic Value of Radiomic Features of 18F-FDG PET/CT in Patients With B-Cell Lymphoma Treated With CD19/CD22 Dual-Targeted Chimeric Antigen Receptor T Cells
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.834288
Abstract: Objective In the present study, we aimed to evaluate the prognostic value of PET/CT-derived radiomic features for patients with B-cell lymphoma (BCL), who were treated with CD19/CD22 dual-targeted chimeric antigen receptor (CAR) T cells. Moreover,… read more here.
Keywords: patients cell; fdg pet; prognostic value; 18f fdg ... See more keywords
Evaluation of Antibody Responses in Patients with B-Cell Malignancies after Two and Three Doses of Anti-SARS-CoV-2 S Vaccination—A Retrospective Cohort Study
Sign Up to like & getrecommendations! Published in 2023 at "Cancers"
DOI: 10.3390/cancers15020524
Abstract: Simple Summary Patients with B-cell malignancies benefit from the third vaccination against SARS-CoV-2 with regards to antibody production. In this cohort, patients with B-cell malignancies experienced greater difficulties in developing neutralizing antibodies, particularly under active… read more here.
Keywords: patients cell; vaccination; antibody; anti sars ... See more keywords
Impact of Aberrant Myeloid Antigen Expression on Outcomes of Patients with T-cell Acute Lymphoblastic Leukemia.
Sign Up to like & getrecommendations! Published in 2017 at "Oman medical journal"
DOI: 10.5001/omj.2017.36
Abstract: OBJECTIVES To evaluate the impact of myeloid antigen expression on complete remission (CR), event-free survival (EFS), and overall survival (OS) in patients with T-cell acute lymphoblastic leukemia (T-ALL) treated with intensive chemotherapy. METHODS We retrospectively… read more here.
Keywords: antigen expression; cell acute; myeloid antigen; patients cell ... See more keywords